Insider Trading Signals — October 21, 2026 — After Hours — Last 16 Hours (Pacific Time)

Executive Summary

Insider activity over the past 16 hours is heavily skewed toward selling, with sales dominating both in count and total dollar value across a wide range of sectors — from biotech to big tech to industrials. The most notable transactions include United Therapeutics CEO Martine Rothblatt offloading $5.26M in stock and a coordinated multi-insider sell-off at Ginkgo Bioworks, where the CEO, President/Founder, CFO, and a director all sold shares simultaneously. On the buy side, activity is modest but present, with a handful of CFOs and fund executives stepping in at smaller dollar amounts — a mildly constructive signal worth watching.

Activity Breakdown

Net Signal: 🔴 Bearish — Net selling of approximately $12.6M over the period. Sales outnumber purchases nearly 3-to-1 by count and more than 20-to-1 by dollar value.

Top Notable Transactions

🔴 United Therapeutics (UTHR) — Strong Bearish

• Insider: Martine A. Rothblatt, Chairperson & CEO
• Transaction: Sale of ~$5.26M
• Signal: Strong Bearish
• Context: A CEO and Chairperson liquidating over $5M is the single largest transaction in this window and carries significant weight given the seniority of the seller.

🔴 Ginkgo Bioworks (DNA) — Strong Bearish (Cluster)

• Insider: Jason R. Kelly, CEO & Founder
• Transaction: Sale of ~$463,352
• Signal: Strong Bearish
• Context: Part of a coordinated four-insider sell-off at DNA — CEO, President/Founder, CFO, and a director all sold on the same day, a rare and highly notable cluster signal.

🔴 Ginkgo Bioworks (DNA) — Strong Bearish (Cluster)

• Insider: Reshma P. Shetty, President & Founder
• Transaction: Sale of ~$417,607
• Signal: Strong Bearish
• Context: Shetty's sale mirrors the CEO's transaction almost exactly in timing, reinforcing the cluster sell signal at DNA.

🔴 Ginkgo Bioworks (DNA) — Moderate Bearish (Cluster)

• Insider: Barry Canton, Director & 10% Owner
• Transaction: Sale of ~$417,607
• Signal: Strong Bearish
• Context: A 10% owner selling alongside multiple co-founders and the CFO amplifies the bearish cluster signal significantly.

🔴 Disc Medicine (IRON) — Strong Bearish

• Insider: Kevin Bitterman, Director
• Transaction: Sale of ~$3.35M over three trading days
• Signal: Strong Bearish
• Context: A multi-day, multi-million-dollar director exit is a meaningful signal, particularly given the sustained nature of the selling.

🔴 Meta Platforms (META) — Moderate Bearish

• Insider: Javier Olivan, Chief Operating Officer
• Transaction: Sale of ~$1.11M
• Signal: Moderate Bearish
• Context: A seven-figure sale by Meta's COO at a large-cap name draws attention, though routine executive sales at mega-caps are common.

🔴 PACS Group (PACS) — Moderate Bearish

• Insider: Jason Hulse Murray, Co-Founder, CEO & Chairman
• Transaction: Sale of ~$2.18M
• Signal: Moderate Bearish
• Context: A co-founder and CEO selling over $2M is a notable signal, especially given the triple-role seniority of the seller.

🔴 TD SYNNEX (SNX) — Moderate Bearish

• Insider: Reyna Thompson, President, North America
• Transaction: Sale of ~$604,483
• Signal: Moderate Bearish
• Context: A division president offloading over $600K is a meaningful transaction at a major technology distribution company.

🔴 Analog Devices (ADI) — Moderate Bearish

• Insider: Richard C. Puccio Jr., CFO
• Transaction: Sale of ~$584,190
• Signal: Moderate Bearish
• Context: A CFO selling over half a million at a large-cap semiconductor firm is worth monitoring given ADI's sector sensitivity.

🔴 Castle Biosciences (CSTL) — Moderate Bearish

• Insider: Derek J. Maetzold, President, CEO & Director
• Transaction: Sale of ~$462,567
• Signal: Moderate Bearish
• Context: A CEO and director selling nearly $500K at a diagnostics-focused biotech adds to the broader healthcare insider selling trend in this window.

🟢 Rapport Therapeutics (RAPP) — Moderate Bullish

• Insider: Troy A. Ignelzi, CFO
• Transaction: Purchase of ~$143,550
• Signal: Moderate Bullish
• Context: A CFO buying stock with personal funds is one of the more credible bullish signals — insiders rarely buy unless they see value ahead.

🟢 Dynex Capital (DX) — Moderate Bullish

• Insider: Byron L. Boston, Co-CEO & Chairman
• Transaction: Purchase of ~$99,970
• Signal: Moderate Bullish
• Context: A Co-CEO and Chairman buying nearly $100K in a mortgage REIT signals personal conviction in the company's near-term outlook.

🟢 Cornerstone Total Return Fund (CRF) — Moderate Bullish

• Insider: Joshua Bradshaw, Vice Chairman & President
• Transaction: Purchase of ~$117,600
• Signal: Moderate Bullish
• Context: Bradshaw also purchased ~$97,280 in the related Cornerstone Strategic Investment Fund (CLM) in the same window — a dual-fund buy from the same executive is a coordinated bullish signal.

Pattern Analysis

🔴 Ginkgo Bioworks (DNA) — Multi-Insider Cluster Sell

• Net Signal: Strongly Bearish
• Companies: Ginkgo Bioworks (DNA)
• Total Value: ~$1.31M across four insiders (CEO, President/Founder, CFO, Director/10% Owner)
• Four insiders at the same company selling on the same day is one of the most significant bearish cluster signals possible. When founders, C-suite, and a major shareholder all exit simultaneously, it warrants serious attention regardless of stated reasons.

🟢 Cornerstone Funds — Dual-Fund Executive Purchase

• Net Signal: Moderately Bullish
• Companies: Cornerstone Total Return Fund (CRF), Cornerstone Strategic Investment Fund (CLM)
• Total Value: ~$214,880
• Joshua Bradshaw purchasing shares in both Cornerstone funds in the same window suggests deliberate, conviction-driven buying rather than a routine or incidental transaction.

🔴 Biotech/Pharma Sector — Broad Executive Selling

• Net Signal: Bearish
• Companies: United Therapeutics (UTHR), Disc Medicine (IRON), Enliven Therapeutics (ELVN), Oric Pharmaceuticals (ORIC), Castle Biosciences (CSTL), Ginkgo Bioworks (DNA)
• Total Value: ~$10.1M in sales
• Multiple biotech and pharma executives across different companies are selling in the same window, suggesting sector-wide profit-taking or caution rather than company-specific concerns alone.

🟢 CFO Buying — Contrarian Signal

• Net Signal: Moderately Bullish
• Companies: Rapport Therapeutics (RAPP), Dynex Capital (DX)
• Total Value: ~$243,520
• CFO purchases are among the most credible insider buy signals — these executives have the deepest visibility into company financials and rarely buy unless they believe shares are undervalued.

Sector Breakdown

Biotechnology & Pharmaceuticals 🔴 (Bearish)

• Net Signal: ~-$10.1M (selling dominant)
• Notable: United Therapeutics (UTHR), Disc Medicine (IRON), Ginkgo Bioworks (DNA), Enliven Therapeutics (ELVN), Oric Pharmaceuticals (ORIC), Castle Biosciences (CSTL), Rapport Therapeutics (RAPP — buy)
• The sector accounts for the majority of insider selling in this window, with only one CFO purchase providing a counterpoint to an otherwise bearish picture.

Technology (Large-Cap) 🔴 (Moderately Bearish)

• Net Signal: ~-$1.75M (selling)
• Notable: Meta Platforms (META), Analog Devices (ADI), TD SYNNEX (SNX), Samsara (IOT), Blend Labs (BLND), Intapp (INTA)
• Broad-based tech selling across large and mid-cap names, though no single transaction is alarming on its own — routine executive sales are common in this sector.

Healthcare Services 🔴 (Moderately Bearish)

• Net Signal: ~-$2.18M (selling)
• Notable: PACS Group (PACS)
• The PACS Group CEO's $2.18M sale stands out as the dominant signal in this sub-sector.

Industrials / Materials 🔴 (Moderately Bearish)

• Net Signal: ~-$288K (selling)
• Notable: Worthington Steel (WS)
• A single notable sale from a division president; limited data to draw broad sector conclusions.

Financials / REITs 🟢 (Moderately Bullish)

• Net Signal: ~+$100K (buying)
• Notable: Dynex Capital (DX — buy), Cornerstone funds (CRF, CLM — buy)
• The only sector showing net insider buying, with a Co-CEO and a fund president both stepping in — a constructive signal for income-oriented financial names.

Telecom 🔴 (Mildly Bearish)

• Net Signal: ~-$49K (selling)
• Notable: Verizon (VZ)
• A small EVP sale at a mega-cap; low signal strength on its own.

Utilities / Water 🟢 (Mildly Bullish)

• Net Signal: ~+$40K (buying)
• Notable: York Water (YORW)
• A director purchase at a small-cap utility; modest but directionally positive.

Market Implications

The dominant theme from this 16-hour window is broad insider selling, particularly concentrated in biotech and pharma. When multiple unrelated executives across different healthcare companies all choose to reduce exposure in the same window, it can reflect sector-level caution — whether driven by valuation concerns, regulatory uncertainty, or anticipation of upcoming catalysts that may disappoint. The Ginkgo Bioworks cluster sell is the single most significant signal of the session and deserves close monitoring.

On the buy side, the activity is modest in dollar terms but meaningful in quality. CFO purchases at Rapport Therapeutics and Dynex Capital, combined with the dual-fund buy from the Cornerstone executive, suggest pockets of genuine insider conviction in select financial and small-cap names. These are the types of purchases — personal money, senior executives, open-market buys — that historically carry the most predictive weight.

The overall picture leans bearish for the near term, particularly in biotech and pharma. However, the concentrated nature of the selling (a few large transactions driving the total) means investors should evaluate each situation individually rather than reading the aggregate as a broad market warning signal.

👉 Vlad's Key Takeaways

• 🔴 Ginkgo Bioworks (DNA): Four insiders — CEO, President/Founder, CFO, and a 10% owner/director — all sold shares in the same window; this is the most significant cluster sell signal of the session.
• 🔴 United Therapeutics (UTHR): CEO and Chairperson Martine Rothblatt sold ~$5.26M — the single largest transaction in this window by a wide margin.
• 🔴 PACS Group (PACS): Co-Founder, CEO, and Chairman Jason Murray sold ~$2.18M; triple-role seniority makes this a high-weight bearish signal.
• 🔴 Disc Medicine (IRON): Director Kevin Bitterman sold ~$3.35M over three trading days — sustained, multi-day selling is a more deliberate signal than a one-off transaction.
• 🔴 Meta Platforms (META): COO Javier Olivan sold ~$1.11M; notable at a mega-cap but routine executive sales at META are common.
• 🔴 Biotech/Pharma sector: Six companies in the space showed insider selling totaling ~$10.1M — the most concentrated sector-level bearish signal in this window.
• 🟢 Rapport Therapeutics (RAPP): CFO Troy Ignelzi bought ~$143,550 — CFO open-market purchases are among the most credible bullish signals available.
• 🟢 Dynex Capital (DX): Co-CEO and Chairman Byron Boston bought ~$99,970 — a chairman buying in a mortgage REIT signals rate-environment confidence.
• 🟢 Cornerstone Funds (CRF / CLM): Executive Joshua Bradshaw bought ~$214,880 across both funds simultaneously — a coordinated, conviction-driven bullish signal for income investors.
• 🔴 Analog Devices (ADI): CFO Richard Puccio sold ~$584,190 — a large-cap semiconductor CFO sale worth watching given the sector's macro sensitivity.
• 🔴 TD SYNNEX (SNX): North America President Reyna Thompson sold ~$604,483 — a division president exit at a major tech distributor.
• 🔴 Selling-to-buying ratio: Sales outpaced purchases roughly 20-to-1 by dollar value (~$13.2M vs. ~$606K) — the overall session signal is bearish.
• 🟢 Financials/REITs: The only sector with net insider buying; small in dollar terms but directionally notable amid broader selling pressure.
• 🟡 Grace Therapeutics (GRCE): Opaleye Management (10% owner/director) bought ~$8,001 — a very small purchase; signal strength is low but directionally positive for a micro-cap name.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Insider transactions can have many motivations beyond stock outlook.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/